Alvotech to acquire Baliopharm

Acquisition provides Alvotech with complimentary capabilities in biosimilar development.

Eef Schimmelpennink, CEO of Alvotech, said: “The acquisition of Baliopharm significantly strengthens our R&D platform and will provide Alvotech with enhanced state-of-the-art development capabilities and brings key biosimilar expertise in house. This acquisition shows our dedication to be one of the global leaders in the high-growth biopharmaceutical industry.”

He furthermore had this to say about the acquisition: “Alvotech and Baliopharm have worked closely together for the past 2 years and the company has been involved in Alvotech’s biosimilar programs. We are convinced that the integration of Baliopharm’s extensive experience will prove crucial into Alvotech’s current platform and allow us to accelerate our programs and be a key factor in bringing timely high-quality biosimilars to the market.”